Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer

Nanomedicine. 2023 Nov:54:102707. doi: 10.1016/j.nano.2023.102707. Epub 2023 Sep 17.

Abstract

Purpose: There are four kinds of taxanes: solvent-based paclitaxel (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel. This study aims to retrospectively evaluate the efficacy of different taxanes on neoadjuvant systemic treatment (NST) in breast cancer.

Methods: Patients who were diagnosed with breast cancer and had received integral NST from August 2013 to April 2022 were enrolled. The efficacy was divided into total pathological complete response (total-pCR), breast pathological complete response (breast-pCR), and axillary pathological complete response (axillary-pCR) for in-depth analysis and discussion.

Results: The choice of taxane was an independent risk factor for total-pCR and breast-pCR rates. The highest total-pCR and breast-pCR rates were found in the Nab-P group. The difference was not significant among all the taxanes in the axillary-pCR rate.

Conclusion: Nab-P significantly improved the total-pCR and breast-pCR rates. It should be the first choice among taxanes in NST for breast cancer.

Keywords: Docetaxel; Liposomal paclitaxel; Nanoparticle albumin-bound paclitaxel; Neoadjuvant systemic treatment; Solvent-based paclitaxel.

MeSH terms

  • Albumin-Bound Paclitaxel / therapeutic use
  • Albumins
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Docetaxel / therapeutic use
  • Female
  • Humans
  • Nanoparticles*
  • Neoadjuvant Therapy
  • Paclitaxel / therapeutic use
  • Retrospective Studies
  • Taxoids / therapeutic use

Substances

  • Docetaxel
  • Albumin-Bound Paclitaxel
  • Paclitaxel
  • Albumins
  • Taxoids